Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025

Maternal respiratory syncytial virus (RSV) vaccine and nirsevimab, a long-acting monoclonal antibody for infants aged 0-7 months and children aged 8-19 months who are at increased risk for severe RSV disease, became widely available for prevention of severe RSV disease among infants and young children during the 2024-25 RSV season. To evaluate the association between availability of these products and infant and child RSV-associated hospitalization rates, the rates among children aged <5 years were compared for the 2024-25 and 2018-20 RSV seasons using data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN). Among infants aged 0-7 months (eligible for protection with maternal vaccination or nirsevimab), 2024-25 RSV-associated hospitalization rates were lower compared with 2018-20 pooled rates (estimated relative rate reductions of 43% [RSV-NET: 95% CI = 40%-46%] and 28% [NVSN: 95% CI = 18%-36%]). The largest estimated rate reduction was observed among infants aged 0-2 months (RSV-NET: 52%, 95% CI = 49%-56%; NVSN: 45%, 95% CI = 32%-57%) and during peak hospitalization periods (December-February). These findings support Advisory Committee on Immunization Practices' recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants and highlight the importance of implementing the recommendations to protect infants as early in the RSV season as possible, before peak transmission, and for infants born during the RSV season, within the first week of life, ideally during the birth hospitalization.

Authors

Institutions

Publication Details

Journal
MMWR Morbidity and Mortality Weekly Report
Published
2025-05-08
DOI
https://doi.org/10.15585/mmwr.mm7416a1
Citations
20
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
27.08

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025

Pam Daily Kirley, Lucy S Witt, Elizabeth Doran, Jennifer E. Schuster et al.
20 citations
MMWR Morbidity and Mortality Weekly Report
Respiratory viral infections research
27.08
article

Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025

Pam Daily Kirley, Lucy S Witt, Elizabeth Doran, Jennifer E. Schuster, Daniel C. Payne, Khalil Harbi, Ruth Lynfield, Fatimah S. Dawood, Daewi Kim, Eileen J. Klein, Patricia Ryan, Yadira Salazar-Sanchez, Monica E. Patton, Geoffrey A. Weinberg, Natasha Halasa, William Schaffner, Erica Mumm, Ariana P. Toepfer, Peter G. Szilagyi, Heidi L. Moline, Julie A. Boom, F. RAYMOND KEATING, Ayzsa Tannis, James Meek, Francesca Pacheco, Brenda L. Tesini, Fiona P. Havers, Rangaraj Selvarangan, Mary Allen Staat, John V. Williams, Anne Thomas, Christopher A. Taylor, Leah Goldstein, Laura S Stewart, Nisha B. Alden, Janet A. Englund, Marian G. Michaels, Kyle P. Openo, Bridget J. Anderson, Michael Whitaker, Christina B. Felsen, Leila C. Sahni, Breanna Kawasaki, Huong Pham, Melissa Sutton, Arthur Reingold, H. Keipp Talbot
article en
20 citations

Abstract

Maternal respiratory syncytial virus (RSV) vaccine and nirsevimab, a long-acting monoclonal antibody for infants aged 0-7 months and children aged 8-19 months who are at increased risk for severe RSV disease, became widely available for prevention of severe RSV disease among infants and young children during the 2024-25 RSV season. To evaluate the association between availability of these products and infant and child RSV-associated hospitalization rates, the rates among children aged <5 years were compared for the 2024-25 and 2018-20 RSV seasons using data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN). Among infants aged 0-7 months (eligible for protection with maternal vaccination or nirsevimab), 2024-25 RSV-associated hospitalization rates were lower compared with 2018-20 pooled rates (estimated relative rate reductions of 43% [RSV-NET: 95% CI = 40%-46%] and 28% [NVSN: 95% CI = 18%-36%]). The largest estimated rate reduction was observed among infants aged 0-2 months (RSV-NET: 52%, 95% CI = 49%-56%; NVSN: 45%, 95% CI = 32%-57%) and during peak hospitalization periods (December-February). These findings support Advisory Committee on Immunization Practices' recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants and highlight the importance of implementing the recommendations to protect infants as early in the RSV season as possible, before peak transmission, and for infants born during the RSV season, within the first week of life, ideally during the birth hospitalization.

MMWR Morbidity and Mortality Weekly ReportVol. 74(16)
Visual Health Information (US)
Bill and Melinda Gates Foundation, Pfizer, AstraZeneca, Sanofi, New York State Department of Health, Minnesota Department of Health, Emory University, American Pharmacists Association, International Maternal Pediatric Adolescent AIDS Clinical Trials Network, Moderna, National Institutes of Health, Genentech, Abbott Diagnostics, Sanofi Pasteur, National Institute of Allergy and Infectious Diseases
Openalex Percentile: Top 0%
Respiratory viral infections research
27.08
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.